PACIRA BIOSCIENCES, INC. Net Income (Loss) Attributable to Parent, Diluted
PACIRA BIOSCIENCES, INC. (PCRX) reported Net Income (Loss) Attributable to Parent, Diluted of $7.03 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2026-02-26
- PACIRA BIOSCIENCES, INC. net income (loss) attributable to parent, diluted for the quarter ending 2025-06-30 was -$4.85M, a 124.67% decline year-over-year.
- PACIRA BIOSCIENCES, INC. net income (loss) attributable to parent, diluted for the quarter ending 2025-03-31 was $4.81M, a 51.92% decline year-over-year.
- PACIRA BIOSCIENCES, INC. net income (loss) attributable to parent, diluted for the quarter ending 2024-12-31 was $16.04M, a 44.66% decline year-over-year.
- PACIRA BIOSCIENCES, INC. net income (loss) attributable to parent, diluted for the quarter ending 2024-09-30 was -$143.47M, a 1306.92% decline year-over-year.
- PACIRA BIOSCIENCES, INC. net income (loss) attributable to parent, diluted for fiscal 2025 was $7.03M.
- PACIRA BIOSCIENCES, INC. net income (loss) attributable to parent, diluted for fiscal 2024 was -$99.56M, a 316.11% decline from fiscal 2023.
- PACIRA BIOSCIENCES, INC. net income (loss) attributable to parent, diluted for fiscal 2023 was $46.07M, a 189.58% increase from fiscal 2022.
- PACIRA BIOSCIENCES, INC. net income (loss) attributable to parent, diluted for fiscal 2022 was $15.91M, a 62.10% decline from fiscal 2021.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 6 month | Net Income (Loss) Attributable to Parent, Diluted 9 month | Net Income (Loss) Attributable to Parent, Diluted 12 month |
|---|---|---|---|---|
| 2025-12-31 | $7.03M 10-K · filed 2026-02-26 | |||
| 2025-06-30 | -$4.85M 10-Q · filed 2025-08-05 | -$35.00K 10-Q · filed 2025-08-05 | $16.01M derived: sum of 3 quarters · filed 2026-02-26 | -$127.46M derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-03-31 | $4.81M 10-Q · filed 2025-05-08 | $20.85M derived: sum of 2 quarters · filed 2026-02-26 | -$122.61M derived: sum of 3 quarters · filed 2026-02-26 | -$102.97M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | $16.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$127.42M derived: sum of 2 quarters · filed 2026-02-26 | -$107.78M derived: sum of 3 quarters · filed 2026-02-26 | -$99.56M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$143.47M 10-Q · filed 2024-11-06 | -$123.82M derived: sum of 2 quarters · filed 2025-08-05 | -$115.60M 10-Q · filed 2024-11-06 | -$84.83M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $19.65M 10-Q · filed 2025-08-05 | $29.66M 10-Q · filed 2025-08-05 | $58.64M derived: sum of 3 quarters · filed 2026-02-26 | $70.53M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $10.01M 10-Q · filed 2025-05-08 | $38.99M derived: sum of 2 quarters · filed 2026-02-26 | $50.88M derived: sum of 3 quarters · filed 2026-02-26 | $77.67M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $28.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $40.87M derived: sum of 2 quarters · filed 2026-02-26 | $67.66M derived: sum of 3 quarters · filed 2026-02-26 | $46.07M 10-K · filed 2026-02-26 |
| 2023-09-30 | $11.89M 10-Q · filed 2024-11-06 | $38.68M derived: sum of 2 quarters · filed 2024-11-06 | $17.09M 10-Q · filed 2024-11-06 | $5.93M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $26.79M 10-Q · filed 2024-07-30 | $6.23M 10-Q · filed 2024-07-30 | -$5.96M derived: sum of 3 quarters · filed 2025-02-27 | -$6.65M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$19.54M 10-Q · filed 2024-05-07 | -$32.75M derived: sum of 2 quarters · filed 2025-02-27 | -$33.44M derived: sum of 3 quarters · filed 2025-02-27 | -$12.53M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$13.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$13.91M derived: sum of 2 quarters · filed 2025-02-27 | $7.01M derived: sum of 3 quarters · filed 2025-02-27 | $15.91M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$693.00K 10-Q · filed 2023-11-02 | $20.22M derived: sum of 2 quarters · filed 2023-11-02 | $29.12M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $20.91M 10-Q · filed 2023-08-02 | $28.78M 10-Q · filed 2023-08-02 | ||
| 2021-12-31 | -$5.13M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $12.53M derived: sum of 2 quarters · filed 2024-02-29 | $31.61M derived: sum of 3 quarters · filed 2024-02-29 | $41.98M 10-K · filed 2024-02-29 |
| 2021-09-30 | $17.66M 10-Q · filed 2022-11-03 | $36.74M derived: sum of 2 quarters · filed 2022-11-03 | $47.11M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $19.08M 10-Q · filed 2022-08-03 | $29.45M 10-Q · filed 2022-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |